Growth Inhibition of Malignant Melanoma by Intermediate Frequency Alternating Electric Fields, and the Underlying Mechanisms

被引:13
作者
Chen, H. [2 ]
Liu, R. [1 ]
Liu, J. [3 ]
Tang, J. [1 ]
机构
[1] Tsinghua Univ, Dept Bioengn, Beijing 100084, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 4, Dept Oncol, Liuzhou, Peoples R China
[3] Cent S Univ, Xiangya Sch Med, Dept Oncol, Changsha, Hunan, Peoples R China
关键词
INTERMEDIATE FREQUENCY; ALTERNATING ELECTRIC FIELD; MELANOMA; APOPTOSIS; ANGIOGENESIS; CD34; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF); ANGIOGENESIS INHIBITORS; VASCULAR-PERMEABILITY; CANCER-THERAPY; LUNG-CANCER; CELL; ZD6474; TUMORS;
D O I
10.1177/147323001204000109
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
OBJECTIVE: This study investigated the antitumour effects of intermediate frequency alternating electric fields (IF-AEF) in a murine melanoma cell line (B16F10) and a mouse tumour model. METHODS: IF-AEF was applied at 100 kHz. Proliferation of B16F10 cells in vitro was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. IF-AEF was applied in vivo to mice bearing B16F10 tumours. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay for apoptosis, and immunohistochemical detection of CD34 and vascular endothelial growth factor (V'EGF), were performed. RESULTS: IF-AEF inhibited the proliferation of B16F10 cells in an electrical intensity and time-dependent manner. Treatment with IF-AEF for 7 days significantly inhibited the growth of tumours compared with untreated controls. IF-AEF induced apoptosis in vivo and reduced CD34-positive cell numbers; CD34 is a special marker of microvessel density. CONCLUSION: IF-AEF reduced microvessel density related to tumour growth and may serve as a therapeutic strategy for cancer treatment.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 27 条
[1]   Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways [J].
Bates, DO ;
Heald, RI ;
Curry, FE ;
Williams, B .
JOURNAL OF PHYSIOLOGY-LONDON, 2001, 533 (01) :263-272
[2]  
BREM S, 1976, CANCER RES, V36, P2807
[3]  
Denekamp J, 1999, EUR J CLIN INVEST, V29, P733
[4]   Overview of angiogenesis: Biologic implications for antiangiogenic therapy [J].
Ellis, LM ;
Liu, WB ;
Ahmad, SA ;
Fan, F ;
Jung, YD ;
Shaheen, RM ;
Reinmuth, N .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :94-104
[5]  
Elson E., 1995, The Biomedical Engineering Handbook, P1417
[6]   Angiogenesis inhibitors in clinical development; where are we now and where are we going? [J].
Eskens, FALM .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :1-7
[7]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[8]  
Folkman J, 1992, Semin Cancer Biol, V3, P65
[9]   Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects [J].
Garbe, Claus ;
Eigentler, Thomas K. ;
Keilholz, Ulrich ;
Hauschild, Axel ;
Kirkwood, John M. .
ONCOLOGIST, 2011, 16 (01) :5-24
[10]   In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies [J].
Garon, Edward B. ;
Sawcer, David ;
Vernier, P. Thomas ;
Tang, Tao ;
Sun, Yinghua ;
Marcu, Laura ;
Gundersen, Martin A. ;
Koeffler, H. Phillip .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (03) :675-682